Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
standardized walnut antigen
- Development stage
- Unknown
- Lead developer
- Nipponham Foundation for the Future of Food
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Standardized walnut antigen is an allergen extract developed for oral immunotherapy (OIT) to treat severe walnut allergy. It is currently being evaluated in the EXLOW study, a multicenter, randomized, double-blind, placebo-controlled trial in Japan. The treatment involves the oral administration of very low, standardized doses of walnut protein (specifically 3 mg or 30 mg) to induce immunological desensitization. The primary goal is to modulate the immune response, measured by changes in walnut-specific IgG4 and IgE levels, thereby increasing the threshold for allergic reactions. The development is sponsored by the Nipponham Foundation for the Future of Food (NFFF).
- Other names
- walnut allergen extractwalnut protein
02
Targets
TCR (T cell antigen receptor complex)Walnut allergen-specific Immunoglobulin E
Beyond the preview
Go deeper on standardized walnut antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on standardized walnut antigen.